AMR Dx Global


Research Network: 2019-01-01 - 2020-10-31
Total sum awarded: €50 000

AMR Dx Global is a transnational, multi-sectorial, multi-stakeholder and interdisciplinary network focussed on rapid diagnostics training and capacity building to tackle the global threat of antimicrobial resistance with a One Health approach. The network is coordinated by the University of Edinburg and brings together partners from 18 countries including international organisations like WHO, FIND, AMREF and ICAN. AMR Dx Global will develop a Strategic Action Plan on training to support the formation of the JPIAMR-VRI and focus on Diagnostics as one of the six priority topics of the JPIAMR Strategic Research Agenda. AMR Dx Global evolved from the successful JPIAMR Working Group AMR-RDT, which identified barriers to development, implementation and use of rapid diagnostics to tackle AMR. The findings of AMR-RDT has been published in Nature Reviews Microbiology and Lancet Infectious Diseases for publication. As before, AMR Dx Global has assembled an outstanding group of experts selected to match the scope of the JPIAMR VRI. The new network provides exceptional access to and input from the leading national and international institutions, networks and activities in the field, which amplifies its immediate reach. Most importantly, the extensive coverage of existing global, international and national initiatives relevant to AMR, diagnostics, training, teaching and capacity building constitutes an exceptional opportunity for JPIAMR-VRI to receive input to its strategy and mitigate the risk of duplication amongst the many emerging transnational initiatives on AMR. AMR Dx Global will run a twelve-month programme including two major meetings and structured data collection on existing strategies, needs and gaps in AMR diagnostics training and capacity building to develop the Strategic Action Plan on training for Diagnostics. The framework for AMR Dx Global and its ultimate vision is the set-up of a JPIAMR Virtual School of Diagnostics as part of the JPIAMR-VRI. Such Virtual School would create world-leading opportunity to connect the global AMR diagnostics community and stakeholders with the next generation of AMR scientists and turn the challenge of AMR into an opportunity for the next generation of researchers and the sustainable development goals.

Read More
Read Less
  • Till Bachmann, University of Edinburgh, United Kingdom (Coordinator)
  • Frank Bier, Fraunhofer Institute for Cell Therapy and Immunology, Germany (Observer)
  • Gerd Luedke, Curetis GmbH, Germany (Observer)
  • Guido Werner, Robert Koch Institute, Germany (Observer)
  • Gunnar Skov Simonsen, University Hospital of North Norway, Norway (Observer)
  • Gyorgy Abel, Lahey Hospital & Medical Center and Harvard Medical School, USA (Observer)
  • Harald Peter, Fraunhofer Institute for Cell Therapy and Immunology, Germany (Observer)
  • Herman Goossens, University of Antwerp, Belgium (Observer)
  • Jacob Moran-Gilad, Ben-Gurion University, Israel (Observer)
  • Jane Carter, Amref International University, Kenya (Observer)
  • Javier R. Ambrosio, National Autonomous University of Mexico (UNAM), Mexico (Observer)
  • Alex van Belkum, BioMérieux, France (Observer)
  • Jean-François de Lavison, Ahimsa Fund, France (Observer)
  • John P. Hays, Erasmus MC University Medical Center, Netherlands (Observer)
  • Jordi Vila, Barcelona Institute for Global Health (ISGlobal), Spain (Observer)
  • Karsten Becker, Friedrich Loeffler-Institute of Medical Microbiology, Germany (Observer)
  • Konstantinos Mitsakakis, Hahn-Schickard, University of Freiburg, Germany (Observer)
  • Neil Woodford, Public Health England, United Kingdom (Observer)
  • Ossama S. Rasslan, Ain Shams University, Egypt (Observer)
  • Pieter Moons, ND4ID (New Diagnostics for Infectious Diseases), Belgium (Observer)
  • Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, India (Observer)
  • Ravi Krishnan Elangovan, Indian Institute of Technology, India (Observer)
  • Alison Prendiville, University of the Arts London, United Kingdom (Observer)
  • Richard Stabler, Liverpool School of Tropical Medicine, United Kingdom (Observer)
  • Rosanna Peeling, Liverpool School of Tropical Medicine, United Kingdom (Observer)
  • Saturnino Luz, University of Edinburgh, United Kingdom (Observer)
  • Shaheen Mehtar, Infection Control Africa Network (ICAN), South Africa (Observer)
  • Sören Schubert, Max von Pettenkofer Institute Munich, Germany (Observer)
  • Stefan Schwarz, Freie Universität Berlin, Germany (Observer)
  • Stephan Harbarth, University Hospitals Geneva, Switzerland (Observer)
  • Susan M. Poutanen, University of Toronto, Canada (Observer)
  • Taslimarif Saiyed, Centre for Cellular and Molecular Platforms, India (Observer)
  • Mark Woolhouse, University of Edinburgh, United Kingdom (Observer)
  • Aman Russom, KTH Royal Institute of Technology, Sweden (Observer)
  • Thomas A. Wichelhaus, Institute of Medical Microbiology and Infection Control, Germany (Observer)
  • Valentina Di Gregori, European Public Health Association and Gvm Care and Research, Italy (Observer)
  • Terri Roberts, MSF, Switzerland (Observer)
  • Amani Ali El- Kholy, University of Cairo, Egypt (Observer)
  • Cassandra Kelly-Cirino, Foundation for Innovative New Diagnostics (FIND), Switzerland (Observer)
  • Daniel Berman, Longitude Prize, Nesta, United Kingdom (Observer)
  • Evelina Tacconelli, University Hospital Tübingen, Germany (Observer)
  • Francis Moussy, World Health Organization (WHO), Switzerland (Observer)

Diagnostics is one of the most important tools to tackle the global threat of antimicrobial resistance (AMR). AMR Dx Global is an international network with partners in 15 countries funded by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as part of the emerging Virtual Research Institute (VRI) and coordinated by University of Edinburgh. The network addresses the needs for teaching and training in relation to AMR diagnostics from a One Health perspective. The network conducted stakeholder mapping, content and delivery roadmapping as well as a demand survey for teaching and training on AMR diagnostics which includes for any type of diagnostics or test to provide information in the wider context of antibiotics, antibacterial resistance or infection such as tests for bacteria, antibiotic resistance genes, antibiotic susceptibilities, infection biomarkers, or antibiotic residues. The AMR Dx provides input into the formation of the JPIAMR VRI and recommends a strong presence of AMR diagnostics in the emerging platform.